Niki BioSolutions, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Niki BioSolutions, Inc. (NIKI) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $50.52 thousand for the 12-month period ending 2024-12-31, per its S-4/A filed 2026-05-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-05-11
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|
| 2024-12-31 | $50.52K S-4/A · filed 2026-05-11 |
| 2023-12-31 | $252.34K S-4/A · filed 2026-05-11 |
| 2022-12-31 | $349.03K 6-K · filed 2025-10-08 |